Midgard

mAbxience

Lugano, Switzerland mabxience.com From their website, Nov 2026

  • GMP

Work here? Claim this listing

About

mAbxience is a vertically integrated biopharmaceutical company that develops and manufactures biologics, with a focus on biosimilars and innovator biologics. It provides end-to-end B2B development and CDMO services from R&D through commercial supply, with sites in Spain and Argentina.

Services

  • Biopharmaceutical development

    Develops biologics with in-house R&D capabilities, including work specialized in biosimilars and innovator biologics.

  • CDMO services

    Provides integrated development and manufacturing services tailored to client requirements, from research batches to commercial batches.

  • Cell line development and banking

    Supports early-stage programs with cell line development and banking activities.

    Cell line development

  • Analytical development

    Develops analytical methods and capabilities to support development, validation, and manufacturing.

  • Process development

    Develops robust and scalable processes for biopharmaceutical programs.

  • Formulation development

    Develops formulations to support clinical and commercial supply.

  • Demo runs

    Performs demo runs as part of early-stage development programs.

  • Clinical manufacturing

    Produces clinical batches under GMP conditions.

4 more services
  • Tech transfer and manufacturing readiness
  • Process validation and analytical validation
  • cGMP manufacturing and commercial supply
  • Quality and regulatory support
Turnaround
  • IND ready in 12 months
  • Manufacturing-ready in 18 months

Capabilities

Assays and studies
  • Antibodies
  • Bioreactors
  • Analytical development
  • Process development
  • Analytical validation
  • Process validation
Scale and capacity
  • 3L-200L small scale GMP production
  • 200L clinical batches
  • 2L to 4,000L bioreactors
  • 6,000L bioreactors coming soon
  • 12,000L batches coming soon
  • Combined capacity of 50,000L
3 more
  • From 50,000L to 74,000L total capacity
  • 3 production sites
  • 5 production lines + 1 coming soon

Instruments and platforms

  • Single-use bioreactors

Modalities and species

Modalities
  • Antibody
  • Bispecific
  • ADC
  • Cell therapy
  • Vaccine
  • Biosimilar

Certifications

As the company states them, with the certificate or registry record where there is one.

  • GMPSelf-reported

    Scope: production plants and small-scale GMP production

Details

Type
CRDMO
Founded
2019
Office
biomanufacturing 2014 – 2015 Genhelix: mAbxience Spain R&D center First launch of
Sites
  • Madrid, Spain
  • Genhelix, Spain
  • Garín, Argentina
  • Munro, Argentina
Serves
Worldwide, Europe, South America

Public records

Parent company
MABXIENCE RESEARCH SL · DE GLEIF
FDA drug establishment registration
3017999629 · ANALYSIS; API MANUFACTURE source

Similar labs